NCT04853017 2025-09-05
AMPLIFY-201
Elicio Therapeutics
Phase 1 Completed
Elicio Therapeutics
Peking University Cancer Hospital & Institute
The Institute of Molecular and Translational Medicine, Czech Republic
IRCCS Azienda Ospedaliero-Universitaria di Bologna